Japanese pharmaceutical company Astellas Pharma last week said that its US subsidiary has acquired Agensys, a University of California-Los Angeles spinout, for $387 million up front plus a maximum of $150 million in potential future milestone payments.
UCLA and the University of California system, which hold an undisclosed equity stake in Agensys, will as a result receive a portion of the upfront payment and any future milestones, making it one of the most lucrative tech-transfer deals in the school’s history.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.